(AAO) Fingolimod for MS offers disease control with no development of uveitis
November 15th 2020Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.
AAO live: Drop-free prophylaxis regimen before cataract surgery lowers treatment burden with caveats
November 15th 2020Speaking during the American Academy of Ophthalmology’s virtual 2020 annual meeting, Neal H. Shorstein, MD, explained how physicians at Kaiser Permanente have been using a prophylactic drop-free drug regimen before cataract surgery for more than a decade. Their regimen is so streamlined that the only drop that patients receive in anticipation of cataract surgery is a supplemental dilation drop instilled preoperatively while they are still in the holding area.
(AAO) Preventing cystoid macular oedema after cataract surgery
November 15th 2020Rudy Nuijts of the University Eye Clinic Maastricht, the Netherlands, discusses the highlights of his AAO 2020 presentation on a combination treatment regimen for lowering the incidence of cystoid macular oedema following category surgery.
(AAO) Alcon showcases advanced IOL technology for presbyopia
November 15th 2020Kristen Brotherson, vice president, US surgical marketing for Alcon, discusses some of the recent advances in cataract surgery-related technologies, including a new advanced lens for patients with presbyopia (AcrySof IQ Vivity IOL).
AAO live: Autologous retinal transplant for larger macular holes gaining traction
November 14th 2020Tamer Mahmoud, MD, PhD, discusses autologous retinal transplant (ART) for macular holes, a procedure he developed, which is providing anatomic hole closure in the vast majority of cases as well as increases in visual acuity.
AAO live: Myopia progression slowed with orthokeratology, multifocal lenses
November 14th 2020In a presentation at the American Academy of Ophthalmology’s virtual 2020 annual meeting, Amy K. Hutchinson, MD, explained that while Myopia has been occurring at epidemic rates worldwide, research has found that the use of orthokeratology and multifocal contact lenses can provide clinically meaningful reductions in myopia progression.
AAO live: Headache with visual loss requires honing of detective skills
November 14th 2020During a presentation at the American Academy of Ophthalmology’s 2020 virtual annual meeting, Kathleeen B. Digre, MD, details how a headache in conjunction with visual loss is a scenario that requires an in-depth examination, including evaluation of the visual fields, pupils, and fundus to gather clues to the diagnosis.
(AAO) Study confirms Phase III results for uveitis treatment
November 14th 2020Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.
(AAO) Alcon virtual booth spotlights latest studies, retina product offerings
November 14th 2020Josh Anderson, head of U.S. retina sales and marketing for Alcon, outlines what attendees will learn including product updates, new technologies, and practice management materials for ophthalmologists and their patients during the COVID-19 pandemic.
(AAO) Considerations when using anti-VEGF for treating AMD
November 14th 2020Prof. Giovanni Staurenghi, chairman of the University Eye Clinic, Department of Biomedical and Clinical Sciences at the University of Milan’s Luigi Sacco Hospital, Italy, discusses his presentation from this year's AAO, including findings from the HARBOR study of macular atrophy in AMD patients treated with ranibizumab.
(AAO) Applying impact of real-world data on day-to-day practice
November 14th 2020Ted Leng, MD, MS, Byers Eye Institute at Stanford, and medical advisor for Verana Health, talks about data insights for retinal surgeons. Steven D. Schwartz, MD, Stein Eye Institute, UCLA, highlights his AAO presentation, “New Insight into Real-World U.S. Injection Data."
(AAO) Genentech provides update on presentations, product portfolio
November 13th 2020Chris Brittain, MBBS, BSc, MBA, MRCOphth, vice president and global head of ophthalmology product development for Genentech, provides an overview of the company’s podium presentations from the PDS with ranibizumab to faricimab.
(AAO) How not to be afraid of performing a posterior capsulorhexis
November 13th 2020Prof. Marie-José Tassignon, past chief and chair, Department of Ophthalmology, Antwerp University and University Hospital Antwerp, Belgium, expands on her upcoming AAO presentation by providing an overview of her novel technique in performing a risk-free posterior capsulorhexis.